E-Cadherin, a cell adhesion molecule, which plays a key role in maintaining the epithelial phenotype, is regarded as an invasion-suppressor gene in light of accumulating evidence from in vitro experiments and clinical observations. In an attempt to clarify the mechanism responsible for inactivation of this gene in carcinomas, we investigated the methylation state around the promoter region by digestion of DNA with the methylation-sensitive restriction enzyme Hpa II, as CpG methylation of the promoter has been postulated to be a mechanism oftranscriptional inactivation of some genes. We found that E-cadherin expression-negative carcinoma cell lines were accompanied by the hypermethylation state, whereas E-cadherin-positive cell lines were not. Furthermore, treatment of E-cadherin-negative carcinoma cells with the demethylating agent 5-azacytidine resulted in reexpression of the gene and reversion of scattered spindle-shaped cells to cells with epithelial morphology. These results suggest that hypermethylation around the promoter may be a mechanism of E-cadherin inactivation in human carcinomas and that treatment of E-cadherin-inactivated cells with a demethylating agent may cause gene expression reversion leading to epithelial morphogenesis with acquisition of the homophilic cell-cell adhesive property.
Cancer metastasis and invasion are closely associated with cellular properties including cell-to-cell adhesiveness. ECadherin, a calcium-dependent cell adhesion molecule, has been demonstrated to play a key role in maintaining the epithelial phenotype (1) . Downregulation of E-cadherin has been reported to occur in various carcinomas (2) (3) (4) (5) and to show a close relationship to invasion (6) and metastasis (7) .
Additional evidence supports the notion that E-cadherin may be an "invasion-suppressor" gene (8) (9) (10) . We proposed a possible mutational mechanism for E-cadherin inactivation after we found that point mutation of one allele and loss of the second allele of the gene occurred in gastric carcinoma cell lines (11) . Mutations of the E-cadherin gene in primary gastric carcinoma have also been reported (12) . However, the mutation rate appeared relatively low in gynecological (13) and breast (14) carcinomas despite the fact that dissociation of cancer cells from the primary tumor is often seen in these carcinomas, suggesting that another mechanism, such as transcriptional inactivation of the gene, may be important. The mechanism responsible for transcriptional inactivation of the E-cadherin gene in carcinoma is poorly understood, although investigations into the E-cadherin promoter have been reported (15, 16) . § Recently, hypermethylation of CpG islands around the 5' regulatory areas of genes has attracted a great deal of attention as a mechanism of transcriptionat inactivation (17) (18) (19) (20) (21) (22) . In normal cells, CpG islands are unmethylated, with the exception of those in the transcriptionally inactive X chromosome or selected genes silenced by parental imprinting (23) . In human cancers, altered CpG methylation has been observed, and it has been suggested that some genes may be inactivated by this mechanism (24) .
In the present study, we found that E-cadherin mRNA expression-negative carcinoma cell lines were accompanied by hypermethylation of the promoter region. Moreover, treatment of E-cadherin-negative carcinoma cells with 5-azacytidine resulted in reexpression of the gene with establishment of cell-cell adhesion and epithelial monolayer formation.
MATERIALS (25) . The probe for E-cadherin was synthesized by the PCR method using E-cadherin cDNA as the template and primers 5'-GGTTATTCCTCCCATCAGCT-3'
(forward) and 5'-CTTGGCTGAGGATGGTGTA-3' (reverse) and was 32P-labeled with a random labeling kit (Boehringer Mannheim). The sequence of this probe encoding an Nterminal region is specific for E-cadherin among known members of the cadherin family (11) . Isolation of the E-Cadherin Promoter and Chloramphenicol Acetyltransferase (CAT) Assay. Genomic clones containing the 5' flanking region of the E-cadherin gene were isolated by screening a human genomic A EMBL3 phage library (Clontech) with the E-cadherin cDNA probe as described (11) .
Positive clones were digested with appropriate restriction enzymes and-subcloned into A ZAP phages (Stratagene) followed by in vivo excision to generate recombinant pBluescript plasmids and were then sequenced with the Sequenase DNA sequencing kit (United States Biochemical).
The -2100 E-cadherin promoter/CAT gene construct was prepared by inserting the HindIII/Nar I fragment of the promoter (Fig. 1) into the promoterless CAT plasmid (pCATAbbreviation: CAT, chloramphenicol acetyltransferase.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. Basic; Promega) and its 5' side-deleted fragment -800, -191, and -91 promoter/CAT constructs were prepared with a deletion kit comprising exonucleases and a DNA ligation system (Takara Shuzo, Kyoto). These deletion fragments had a common 3' end at position +94. The constructs were transfected into SW1116 and MRC5 cells by the electroporation method and their CAT activities were determined as described (25) with some modification. The CAT activities of the various constructs were compared with that of the CAT plasmid containing the simian virus 40 promoter/enhancer (pCAT-Control; Promega). Southern Blot Analysis for the E-Cadherin Promoter Region. Aliquots (10 jig) of DNA were digested with EcoRI and BamHI (EB); EcoRI, BamHI, and Hpa II (EBH); or Hpa II (H) alone, and Southern hybridization was performed as described (25) . The DNA was incubated with each restriction enzyme (10 units per jig of DNA) for 24 h and then with a further 10 units per ,ug of DNA for another 24 h to ensure complete digestion in the appropriate buffer provided by the supplier (Toyobo). The probe used was the Csp45I/BamHI fragment of the E-cadherin promoter shown in Fig. 1 .
Immunofluorostaining of E-Cadherin in Cultured Cells. Cultured cells were fixed in 2% paraformaldehyde and treated with 0.1% Triton X-100 followed by overnight incubation at 4°C with the anti-E-cadherin monoclonal antibody HECD-1 (26 Fig. 1 . The transcription initiation site was determined by primer extension (data not shown). We tested the -2100, -800, -191, and -91 promoter/CAT constructs in SW1116 epithelial cells. When the -191 promoter/CAT construct was transfected, CAT activity was the highest. In MRC5 fibroblasts, CAT activity was low with all constructs tested (Fig. 2) .
Northern Blot Analysis for E-Cadherin mRNA. Ten human carcinoma cell lines (listed in Table 1 ) and fibroblast cell line MRC5 were subjected to analysis. The SW1116, MCF7, and Li7 HM cells were positive, whereas Lu65A, MKN1, T24, Li2l, Li7 NM, HSC41, HSC43, and MRC5 were negative for Ecadherin mRNA expression (Fig. 3) .
E-Cadherin mRNA-Negative Carcinoma Cell Lines Were Accompanied by Hypermethylation of the Promoter. After Southern blot analysis (Fig. 4) The human E-cadherin promoter has been partially characterized (16) . In the present study, we cloned the human E-cadherin promoter region and evaluated its promoter activity by the CAT assay. We found potent promoter activity in the proximal 200-bp region in SW1116 epithelial cells, which contrasted with the low activity in fibroblasts (Fig. 2) , suggesting that this promoter region may contain cis regulatory elements that determine the epithelium-specific promoter activity. These results are largely consistent with those obtained with the mouse E-cadherin promoter (15) .
As far as carcinoma cells are concerned, a previous study showed that the activity of the E-cadherin promoter was reduced in dedifferentiated breast carcinoma cells, assessed by the CAT assay after transfection with the mouse E-cadherin promoter, suggesting negative regulation by cis regulatory elements of the promoter (15) . Furthermore, the E-cadherin promoter (-399/+31) was found not to be active in a nonexpressing human prostate cancer cell line (16 (30) , the von Hippel-Lindau (VHIL) tumor suppressor gene in renal carcinoma (31) , the estrogen receptor gene in breast carcinoma (32) , and the vr-class glutathione S-transferase gene in prostate carcinoma (33) . Our present study showed that the E-cadherin gene may be inactivated by CpG methylation in a wide range of carcinomas of various origins, including lung, liver, stomach, and bladder, suggesting that CpG methylation may be a common mechanism of gene inactivation in human carcinomas. However, it should be noted that CpG methylation may not occur in all E-cadherin-negative immortalized cells, as MRC5 fibroblasts did not seem to be accompanied by hypermethylation (Fig. 4) . It is feasible that the promoter of MRC5 fibroblasts may be methylation-free, as the gene may be repressed by a tissue-specific transcriptional mechanism (15) . Furthermore, CpG methylation of the E-cadherin promoter may also occur in primary carcinomas, because gene inactivation, probably due to CpG methylation, has been observed in many neoplastic samples in vivo (29, 31, (33) (34) (35) and because the mutation frequency of the E-cadherin gene appeared relatively low in primary carcinomas, as discuussed above.
In the present study, we succeeded in inducing reexpression of the E-cadherin gene and reversion to epithelial morphology by treating gastric carcinoma MKN1 cells with 5-azacytidine. This cytidine analog is known to inhibit DNA methylation (36) and it was shown that treatment with 5-aza-2'-deoxycytidine resulted in reexpression of the VIL gene in a renal cell culture line in which the 5' region of the gene was originally hypermethylated and the gene was silenced (31) . The E-cadherinreverted cells formed scattered epithelial colonies, which contrasted with the E-cadherin-negative original cells, suggesting that the treatment caused clonal change of cells in which the E-cadherin promoter may have been demethylated and released from gene silencing. Similar results were obtained with Li21 cells (data not shown). These results suggest that CpG methylation causes E-cadherin gene inactivation. Moreover, they raise the possibility of a therapeutic procedure to reduce malignant phenotypes, such as invasion and metastasis, in carcinoma cells in which the E-cadherin has been silenced by CpG methylation.
In conclusion, we have demonstrated that E-cadherin expression-negative human carcinomas of various origins were accompanied by CpG methylation of the promoter and treatment with a demethylating agent induced reversion to Ecadherin gene expression and led to epithelial morphogenesis, raising the possibility of invasion-suppression therapy for E-cadherin-negative carcinomas.
